Gynecologic Oncology Reports最新文献_第2页

Cost of care associated with utilization of telehealth in clinical trials 与在临床试验中使用远程保健有关的护理成本

IF 1.2

Gynecologic Oncology Reports Pub Date : 2024-10-12 DOI: 10.1016/j.gore.2024.101523

Emily Gleason , Leslie Andriani , Elizabeth A. Tubridy , Destiny Uwawuike , Simon Gunter , Nathanael C. Koelper , Heidi S. Harvie , Emily M. Ko

{"title":"Cost of care associated with utilization of telehealth in clinical trials","authors":"Emily Gleason , Leslie Andriani , Elizabeth A. Tubridy , Destiny Uwawuike , Simon Gunter , Nathanael C. Koelper , Heidi S. Harvie , Emily M. Ko","doi":"10.1016/j.gore.2024.101523","DOIUrl":"10.1016/j.gore.2024.101523","url":null,"abstract":"<div><h3>Objective</h3><div>Due to COVID-19 pandemic restrictions, telehealth was incorporated into standard oncologic care and clinical trial operations. We sought to analyze whether telehealth changed cost of care compared to traditional clinical trial operations.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study of gynecologic oncology patients enrolled in therapeutic clinical trials at a National Cancer Institute designated center, comparing the cost of cancer care on trial pre-TELEhealth (9/30/2019 to 3/15/2020) versus during TELEhealth (3/16/2020 to 8/20/2020). Inclusion required trial participation during both study periods, ≥1 telehealth visit, and identifiable billing records. The analysis was from a healthcare sector perspective. Cost per patient per month on trial was calculated for scheduled (per protocol) and unscheduled (non-protocol) encounters using 2020 national Medicare reimbursement rates, not institution-specific prices. Pairwise t-tests between pre-TELE and TELE periods were performed.</div></div><div><h3>Results</h3><div>Twenty-eight patients were included in the study. The majority of patients (93 %) had ovarian cancer. One patient (4 %) had uterine and 1 (4 %) had concurrent ovarian/uterine cancer. Most patients had advanced-stage disease at diagnosis (93 %). Mean cost per patient per month was similar in pre-TELE and TELE periods ($3797 vs. $4720, p = 0.064). There were no cost differences among scheduled or unscheduled encounters, office or ED visits, admissions, outpatient procedures, nor those billed to study sponsors or patient’s insurer.</div></div><div><h3>Conclusions</h3><div>Incorporating telehealth in gynecologic cancer clinical trials during the COVID-19 pandemic did not increase cost of care and may be a mechanism for decentralizing clinical trials, reducing barriers to trial participation, and improving the value of cancer care.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142539613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pembrolizumab-induced cytokine release syndrome with severe encephalopathy in the setting of clear cell vaginal carcinoma: A case report 彭博利珠单抗诱导的细胞因子释放综合征伴重度脑病（透明细胞阴道癌）：病例报告

IF 1.2

Gynecologic Oncology Reports Pub Date : 2024-10-11 DOI: 10.1016/j.gore.2024.101529

Samantha Metzger, Keely Ulmer, Emily K. Hill

引用次数: 0

Development of diffuse cutaneous squamous cell carcinoma in situ after chemotherapy for ovarian carcinoma and remission with PD1-inhibitor 卵巢癌化疗后出现弥漫性皮肤鳞状细胞原位癌，使用PD1抑制剂后病情缓解

IF 1.2

Gynecologic Oncology Reports Pub Date : 2024-10-11 DOI: 10.1016/j.gore.2024.101528

Jess Durbin , Taylor A. Rives , Dava Piecoro , Charles S. Dietrich

引用次数: 0

Prevalence and genotype distribution of high-risk Human Papillomavirus infection among Vietnamese women in Ho Chi Minh City, Viet Nam: A population-based cross-sectional study 越南胡志明市越南妇女高危人类乳头瘤病毒感染的流行率和基因型分布：基于人口的横断面研究

IF 1.2

Gynecologic Oncology Reports Pub Date : 2024-10-09 DOI: 10.1016/j.gore.2024.101526

Ho Minh Nguyet , Phan Thanh Tam , Quach Kim Ung , To Gia Kien , Le Hong Phuoc

{"title":"Prevalence and genotype distribution of high-risk Human Papillomavirus infection among Vietnamese women in Ho Chi Minh City, Viet Nam: A population-based cross-sectional study","authors":"Ho Minh Nguyet , Phan Thanh Tam , Quach Kim Ung , To Gia Kien , Le Hong Phuoc","doi":"10.1016/j.gore.2024.101526","DOIUrl":"10.1016/j.gore.2024.101526","url":null,"abstract":"<div><h3>Introduction</h3><div>Persistent infection with high-risk <em>Human Papillomavirus</em> (HR-HPV) genotypes are wellknown to increase the risk of cervical cancer significantly. This study aims to determine the prevalence and distribution of high-risk HR-HPV genotypes among women in Ho Chi Minh City (HCMC), Viet Nam.</div></div><div><h3>Methods</h3><div>A population-based cross-sectional study was conducted between June 2020 and September 2020 in all 24 districts of HCMC, Viet Nam. Socio-demographic and behavioral data were collected from 2478 women aged 25 to 65 who had sexual intercourse using a self-administered questionnaire. Vaginal swab specimens from all participants were collected to identify HR-HPV genotypes using Polymerase Chain Reaction (PCR) protocols.</div></div><div><h3>Results</h3><div>The prevalence of HR-HPV infection was 3.5 % (87 women, including 20 cases infected with multi-genotypes), 3.1 % in urban and 0.4 % in rural areas. The most detected HR-HPV genotypes among positive cases were 58 (25.3 %), 52 (21.8 %), 16 (21.8 %), 68 (10.3 %), 51 (10.34 %) and 18 (9.2 %). The prevalence of multi-type HR-HPV genotypes was 0.81 %, of which the most common co-infection genotypes were 52 and 58 (20.0 %), 16 and 56 (10.0 %), and 16 and 39 (10.0 %). The percentages of one-, two-, three-, and four-genotypes of HPV among positive cases were 77.0 %, 16.1 %, 4.6 % and 2.3 %, respectively.</div></div><div><h3>Conclusions</h3><div>Our findings explore a low prevalence of HR-HPV infection in Vietnamese women, of which genotypes 52 and 58 are more popular than 16 and 18. Continuously updated data on the genotype distribution of HPV are helpful for vaccine development and planning preventive activities to prevent HPV-related cancers.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142421495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence and risk factors of silent deep venous thromboembolism before interval debulking surgery in ovarian cancer patients, a tertiary centre experience 卵巢癌患者间歇性去势手术前无声深静脉血栓栓塞症的发病率和风险因素，一家三级中心的经验

IF 1.2

Gynecologic Oncology Reports Pub Date : 2024-10-06 DOI: 10.1016/j.gore.2024.101522

Mohamed Abdelkhalek, Basel Refky, Mohammed Zuhdy, Omar Hamdy, Mohamed Hamdy, Khaled Gaballa, Amr Elalfy

{"title":"Incidence and risk factors of silent deep venous thromboembolism before interval debulking surgery in ovarian cancer patients, a tertiary centre experience","authors":"Mohamed Abdelkhalek, Basel Refky, Mohammed Zuhdy, Omar Hamdy, Mohamed Hamdy, Khaled Gaballa, Amr Elalfy","doi":"10.1016/j.gore.2024.101522","DOIUrl":"10.1016/j.gore.2024.101522","url":null,"abstract":"<div><h3>Objective</h3><div>To determine the prevalence and risk factors for the development of asymptomatic venous thromboembolism (VTE) in ovarian cancer patients who underwent interval cytoreductive surgery after finishing neoadjuvant chemotherapy.</div></div><div><h3>Methods</h3><div>This is a prospective observational trial. Female patients with pathologically proven ovarian cancer who received neoadjuvant chemotherapy without clinical evidence of VTE were included.</div></div><div><h3>Results</h3><div>A total of 107 patients were enrolled in this study. The mean age was 53.37 years, and the mean body mass index (BMI) was 34.11 kg/m<sup>2</sup>. Seven (6.5 %) patients suffered from silent VTE, as documented by bilateral Doppler ultrasound in the pre- and postoperative settings. The mean age of the patients in the VTE group was 56.17 years, and their mean body mass index was 31.71 Kg/m<sup>2</sup>. Their median serum CA125 concentration was elevated (325.6 units/ml). On the other hand, the median D-dimer level was elevated by 678 ng/ml fibrinogen equivalent units (FEUs) in the same group of patients. In the present study, comorbidities did not influence the incidence of VTE, as the 7 patients who were diagnosed with VTE did not have any comorbidities. Most of the patients who were diagnosed with serous adenocarcinoma (71.4 %) or stage IIIc disease (57.1 %) were most likely to develop VTE.</div></div><div><h3>Conclusion</h3><div>Silent VTE is more prevalent in patients with advanced-stage ovarian cancer and serous carcinomas.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142421491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The new FIGO 2023 staging reclassification of patients with FIGO 2009 Stage IVB endometrial cancer correlates to progression-free and overall survival outcomes FIGO 2023 对 FIGO 2009 IVB 期子宫内膜癌患者的新分期重新分类与无进展生存期和总生存期结果相关联

IF 1.2

Gynecologic Oncology Reports Pub Date : 2024-10-05 DOI: 10.1016/j.gore.2024.101527

Monal Garg , Priya Bhati , Pranidha Shree CA , Wesley M. Jose , Sheejamol V.S. , Keechilat Pavithran

{"title":"The new FIGO 2023 staging reclassification of patients with FIGO 2009 Stage IVB endometrial cancer correlates to progression-free and overall survival outcomes","authors":"Monal Garg , Priya Bhati , Pranidha Shree CA , Wesley M. Jose , Sheejamol V.S. , Keechilat Pavithran","doi":"10.1016/j.gore.2024.101527","DOIUrl":"10.1016/j.gore.2024.101527","url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to determine the oncological outcomes of Stage IVB (FIGO 2009) Endometrial cancer patients and its comparison with the new (FIGO 2023) staging.</div></div><div><h3>Methods</h3><div>A Retrospective analysis was conducted between May 30, 2011, and December 30, 2020 on all patients with stage IVB (FIGO 2009 Staging) endometrial cancer. Overall survival (OS) was the primary outcome. Progression-Free Survival (PFS) and comparison with new staging FIGO 2023 were the secondary outcomes. Kaplan-Meier curves and log-rank tests were used to compare the average OS time and PFS between the groups.</div></div><div><h3>Results</h3><div>Fifty-one patients with Stage IVB endometrial cancer (2009 FIGO Staging) were included. Median age was 68 years. Serous histology was found in 24 (47.1 %) patients. After a median follow-up period of 24 months, median OS was 36 months and median PFS was 15 months. FIGO 2023 staging criteria reclassified the stages of 23 patients (45 %). Patients were restaged into Stage IIIB2 (9.8 %), IVA (5.8 %), IVB (55 %) and IVC (29.4 %). Median OS and PFS were not reached for stages IIIB and IVA, while the median OS and median PFS for stage IVB were 36 months and 18 months, respectively. However, patients with stage IVC had lower median OS and PFS of 10 months and 4 months, respectively.</div></div><div><h3>Conclusion</h3><div>The clinical outcomes of patients with Stage IVB are varied depending mainly on the disease distribution. Patients with abdominal or pelvic disease had better survival outcomes and therefore, needed a different categorisation. Thus, FIGO 2023 Staging considers this varied disease distribution and appears to be a better prognostic indicator for this group.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142421492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tisotumab vedotin extravasation injury in a patient with recurrent cervical cancer 一名复发性宫颈癌患者的替妥单抗维多汀外渗损伤

IF 1.2

Gynecologic Oncology Reports Pub Date : 2024-10-02 DOI: 10.1016/j.gore.2024.101525

Ji Son , Katherine E. Cain , Claire A. Marten , Kaitlin W Dwyer , Travis T. Sims , Jolyn S. Taylor

引用次数: 0

Utility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas 利用新一代测序技术明确确定同步性与转移性子宫内膜癌和卵巢癌的克隆性

IF 1.2

Gynecologic Oncology Reports Pub Date : 2024-10-02 DOI: 10.1016/j.gore.2024.101524

Michelle Greenman , Stefania Bellone , Tobias Hartwich , Natalia Buza , Alessandro D. Santin

{"title":"Utility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas","authors":"Michelle Greenman , Stefania Bellone , Tobias Hartwich , Natalia Buza , Alessandro D. Santin","doi":"10.1016/j.gore.2024.101524","DOIUrl":"10.1016/j.gore.2024.101524","url":null,"abstract":"<div><h3>Background</h3><div>Synchronous endometrial and ovarian carcinomas represent up to 10% of all endometrial and ovarian tumors. These are diagnostically challenging cases to determine if they represent dual primary tumors or related metastatic tumors.</div></div><div><h3>Case</h3><div>A 48-year-old was diagnosed with synchronous primary ovarian and endometrial malignancies on pathology based on traditional morphological parameters. However, following next generation sequencing (NGS) of tumors from both the uterus and ovary, the malignancies were unequivocally recognized as primary uterine tumor metastatic to the ovary using mismatch repair protein expression profile and tumor clonality.</div></div><div><h3>Conclusion</h3><div>NGS using FDA-approved commercially available platforms is becoming increasingly utilized to understand the genetic landscape of tumors and select the appropriate targeted therapies for improved outcomes. Simultaneous sequencing of synchronous endometrial and ovarian carcinomas may represent the new gold standard to unequivocally demonstrate tumor clonal relationships, properly classify disease as well as guide the most appropriate adjuvant treatment in these challenging cases.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142421490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Malignant STK11 adnexal tumor harboring a somatic mutation in a woman previously diagnosed with mesothelioma, a case report 曾被诊断为间皮瘤的一名女性体内携带体细胞突变的恶性 STK11 附件肿瘤病例报告

IF 1.2

Gynecologic Oncology Reports Pub Date : 2024-10-01 DOI: 10.1016/j.gore.2024.101521

Christina R. Rutherford , Taylor A. Rives , Dava W. Piecoro , Charles S. Dietrich

{"title":"Malignant STK11 adnexal tumor harboring a somatic mutation in a woman previously diagnosed with mesothelioma, a case report","authors":"Christina R. Rutherford , Taylor A. Rives , Dava W. Piecoro , Charles S. Dietrich","doi":"10.1016/j.gore.2024.101521","DOIUrl":"10.1016/j.gore.2024.101521","url":null,"abstract":"<div><div>STK11 germline pathogenic variants are typically associated with Peutz-Jeghers syndrome, an autosomal dominant disease characterized by hamartomatous polyps in the gastrointestinal tract, hyperpigmented patches, and increased risk of stomach, colorectal, small bowel, and breast cancers (Beggs et al., 2010). Mutations in this gene have also been identified in skin, pancreatic, testicular, and stromal ovarian cancer (Fagerberg et al., 2014). To date, there have been less than 30 cases of ovarian cancer reported associated with mutated STK11 (Bennett et al., 2021). In this report, we discuss a rare case of a STK11 adnexal tumor in a 39-year-old woman previously diagnosed with malignant mesothelioma. After 33 months with no evidence of disease following cytoreductive surgery with HIPEC and adjuvant chemotherapy, a new retroperitoneal lesion was noted on imaging. After resection, molecular testing indicated an STK11 mutation, and histology was consistent with an STK11 adnexal tumor. A high index of suspicion is required to make the diagnosis of STK11 adnexal tumor due to its non-distinct pathology and IHC staining. Due to the rarity of this neoplasm, analysis of current and future cases of the STK11 adnexal tumor is necessary to understand its pathogenesis, genetic mutational analysis, clinical course, and best treatment options.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142421648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Docetaxel induced myositis in the treatment of uterine Leiomyosarcoma: A case report and review of literature 多西他赛在治疗子宫线粒体肉瘤过程中诱发肌炎：病例报告和文献综述

IF 1.2

Gynecologic Oncology Reports Pub Date : 2024-09-30 DOI: 10.1016/j.gore.2024.101519

Nourah Ibrahim , Alon D. Altman

引用次数: 0